INTERIM REPORT JANUARY-MARCH 2015

THE JANUARY-MARCH PERIOD 2015 IN BRIEF

· Net sales amounted to MSEK 0.4 (6.4)
· Net loss for the group was MSEK 15.3 (13.4)
· Loss per share was SEK 0.02 (0.02)
· Cash flow from operating activities was MSEK -19.4 (-13.1)
· Cash and cash equivalents and other short-term investments at the end of the period totaled MSEK 32.2 (8.6)
· Anders Lönner was appointed Executive Chairman of the Board and Maria Sjöberg CEO
· A collaboration was initiated with the German pharmaceutical company Dr. Wolff

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

· The Board of Directors proposes a rights issue of approx. MSEK 230. Underwriting agreements have been obtained equivalent to 100 per cent of the issue, of which Anders Lönner underwrites more than 95 per cent.
· Tanomed AB with a unique cold treatment, was acquired at a value of MSEK 20

CONFERENCE CALL / AUDIOCAST TODAY AT 11.00 A.M. CET
A presentation of the report (in Swedish) will take place today 11.00 a.m. The presentation and slides are available through the corporate website www.karobio.se or by telephone +46 8 566 426 63 (Sweden), +44 20 319 405 44 (UK) or +1 855 269 26 04 (USA). Questions may be submitted over the internet or by telephone.

  
FOR FURTHER INFORMATION, PLEASE CONTACT:
Henrik Palm, CFO, +46 8 608 6076, +46 70 540 4014 or henrik.palm@karobio.se

ABOUT KARO BIO
Karo Bio is a development company with a focus on broadening its activities to cover projects and products closer to market. The company has several projects on the way to the clinical phase. Operations are conducted in Huddinge, Sweden and the share is listed on Nasdaq Stockholm.

The information in this report is such that Karo Bio is required to disclose under the Swedish Securities Market Act. The information was disclosed on April 29, 2015 at 8.15 a.m. CET.